Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735626 | 0.91 | ESR2 (0.50) | ESR2NR1H2HDAC6ADORA1NAMPT | |
| SCHEMBL19303081 | 0.88 | ESR2 (0.52) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL22677816 | 0.83 | ESR2 (0.47) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL31166095 | 0.82 | HDAC6 (0.40) | ESR2HDAC6BRD4CREBBPMAPT | |
| SCHEMBL8555269 | 0.81 | HDAC6 (0.54) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL6421569 | 0.81 | ESR2 (0.55) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL978284 | 0.81 | HDAC6 (0.59) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL22369230 | 0.80 | ESR2 (0.54) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL32660197 | 0.80 | ESR2 (0.54) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL14876121 | 0.80 | NR1H2 (0.60) | ESR2NR1H2HDAC6BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186232-B1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2019-03-27 | — | — | EP | disclosed |
| EP-3186232-B1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2019-03-27 | — | — | EP | disclosed |
| US-9963463-B2 | Urea-substituted indanes as P38 map kinase inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-08 | — | — | US | disclosed |
| US-9963463-B2 | Urea-substituted indanes as P38 map kinase inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-08 | — | — | US | disclosed |
| US-9963463-B2 | Urea-substituted indanes as P38 map kinase inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-08 | — | — | US | disclosed |
| US-20170247390-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247390-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247390-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2017-08-31 | — | — | US | disclosed |
| EP-3186232-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030852-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016030852-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247390-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | MAPK1, MAP3K11, MAPK3 | ESR2 3327/4885NR1H2 704/4885HDAC6 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.